FDA Panel Backs Six Peptides for Compounding, But Legal Access Hangs on Rulemaking

An FDA Pharmacy Compounding Advisory Committee narrowly recommended six of seven peptides for inclusion on the 503A Bulks List—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—with emideltide rejected. The vote advances a nonbinding advisory step, but none of the substances is FDA-approved and final access hinges on proposed and final rulemaking. Available studies are short and small, leaving safety and efficacy data weak. The panel's reconstitution drew scrutiny over conflicts of interest, and payers should expect continued out-of-pocket use and online sourcing, with emphasis on careful medication reconciliation and safety monitoring until more data are available.